In 2022, Mediar Therapeutics, Inc. closed the transaction. The company raised $53,273,679.7384 in its second and final tranche. The company raised $85,034,865.7384 in the transaction.

The company has raised $150,000,000 in funding till date. The transaction was co-led by new investors, Novartis Venture Funds and Sofinnova Capital X FPCI, a fund managed by Sofinnova Partners SAS for $7 million. The transaction included participation from other new investors, Mission BioCapital, LP, Gimv NV, Pureos Partners AG, Bristol-Myers Squibb Company, Eli Lilly, and Company, returning investors, Ono Venture Investment, Inc., Mass General Brigham Ventures, LLC Pfizer Venture Investments LLC.

As part of the transaction, Nandita Shangari of Novartis Venture Funds, Maina Bhaman of Sofinnova Partners SAS and Andreas Jurgeit of Gimv NV will join the board of directors of the company.